Literature DB >> 25947952

Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).

Jeffrey I Cohen1, Julie E Niemela, Jennifer L Stoddard, Stefania Pittaluga, Helen Heslop, Elaine S Jaffe, Kennichi Dowdell.   

Abstract

Severe chronic active Epstein-Barr virus (CAEBV) disease is defined as a severe progressive illness lasting 6 months or longer with infiltration of tissues with EBV-positive lymphocytes, markedly elevated levels of EBV DNA in the blood, and no known immunodeficiency such as HIV. These patients usually have fever, splenomegaly, lymphadenopathy, and may have markedly elevated EBV antibody titers to viral capsid antigen. Although the cause of most cases of severe CAEBV is unknown, one well-documented case was associated with compound heterozygous mutations in PRF1 (perforin 1). Here we report a patient with prolonged severe CAEBV who underwent bone marrow transplant for his disease and subsequently was found to have compound heterozygous mutations in STXBP2 (MUNC18-2) as well as a heterozygous mutation in PRF1 (perforin 1).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25947952      PMCID: PMC4504756          DOI: 10.1007/s10875-015-0168-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  16 in total

1.  Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function.

Authors:  Ilia Voskoboinik; Vivien R Sutton; Annette Ciccone; Colin M House; Jenny Chia; Phillip K Darcy; Hideo Yagita; Joseph A Trapani
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

2.  Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.

Authors:  Marjorie Côte; Mickaël M Ménager; Agathe Burgess; Nizar Mahlaoui; Capucine Picard; Catherine Schaffner; Fahad Al-Manjomi; Musa Al-Harbi; Abdullah Alangari; Françoise Le Deist; Andrew R Gennery; Nathalie Prince; Astrid Cariou; Patrick Nitschke; Ulrich Blank; Gehad El-Ghazali; Gaël Ménasché; Sylvain Latour; Alain Fischer; Geneviève de Saint Basile
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

3.  Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2.

Authors:  Marie Meeths; Miriam Entesarian; Waleed Al-Herz; Samuel C C Chiang; Stephanie M Wood; Wafa Al-Ateeqi; Francisco Almazan; Jaap J Boelens; Henrik Hasle; Marianne Ifversen; Bendik Lund; J Merlijn van den Berg; Britt Gustafsson; Hans Hjelmqvist; Magnus Nordenskjöld; Yenan T Bryceson; Jan-Inge Henter
Journal:  Blood       Date:  2010-06-17       Impact factor: 22.113

4.  Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases.

Authors:  Jan Rohr; Karin Beutel; Andrea Maul-Pavicic; Thomas Vraetz; Jens Thiel; Klaus Warnatz; Ilka Bondzio; Ute Gross-Wieltsch; Michael Schündeln; Barbara Schütz; Wilhelm Woessmann; Andreas H Groll; Brigitte Strahm; Julia Pagel; Carsten Speckmann; Gritta Janka; Gillian Griffiths; Klaus Schwarz; Udo zur Stadt; Stephan Ehl
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

5.  STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5.

Authors:  Valentina Cetica; Alessandra Santoro; Kimberly C Gilmour; Elena Sieni; Karin Beutel; Daniela Pende; Stefania Marcenaro; Florian Koch; Samantha Grieve; Rachel Wheeler; Fang Zhao; Udo zur Stadt; Gillian M Griffiths; Maurizio Aricò
Journal:  J Med Genet       Date:  2010-09       Impact factor: 6.318

6.  A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin.

Authors:  Christina Trambas; Federico Gallo; Daniela Pende; Stefania Marcenaro; Lorenzo Moretta; Carmela De Fusco; Alessandra Santoro; Luigi Notarangelo; Maurizio Arico; Gillian M Griffiths
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

7.  Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.

Authors:  Karin Beutel; Ute Gross-Wieltsch; Thomas Wiesel; Udo Zur Stadt; Gritta Janka; Hans-Joachim Wagner
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

8.  Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation.

Authors:  Harutaka Katano; Mir A Ali; Andriani C Patera; Marta Catalfamo; Elaine S Jaffe; Hiroshi Kimura; Janet K Dale; Stephen E Straus; Jeffrey I Cohen
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

9.  Epstein-Barr virus load in cerebrospinal fluid of patients with chronic active Epstein-Barr virus infection.

Authors:  Shouichi Ohga; Masafumi Sanefuji; Masataka Ishimura; Akihiko Nomura; Hiroyuki Torisu; Ryutaro Kira; Hidetoshi Takada; Yumi Mizuno; Yukumasa Kazuyama; Toshiro Hara
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

10.  Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.

Authors:  Udo zur Stadt; Jan Rohr; Wenke Seifert; Florian Koch; Samantha Grieve; Julia Pagel; Julia Strauss; Brigitte Kasper; Gudrun Nürnberg; Christian Becker; Andrea Maul-Pavicic; Karin Beutel; Gritta Janka; Gillian Griffiths; Stephan Ehl; Hans Christian Hennies
Journal:  Am J Hum Genet       Date:  2009-10       Impact factor: 11.025

View more
  10 in total

1.  MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections.

Authors:  Ryan M McCormack; Eva P Szymanski; Amy P Hsu; Elena Perez; Kenneth N Olivier; Eva Fisher; E Brook Goodhew; Eckhard R Podack; Steven M Holland
Journal:  JCI Insight       Date:  2017-04-20

2.  Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man.

Authors:  Melissa A Levoska; Jeffrey I Cohen; Irini Manoli; Chyi-Chia Richard Lee; Steven S T Ching; Jessica Shand; Deborah Tamura; Kenneth H Kraemer; John J DiGiovanna
Journal:  J Am Acad Dermatol       Date:  2017-09-28       Impact factor: 11.527

Review 3.  Epstein-Barr Virus-Specific Immune Control by Innate Lymphocytes.

Authors:  Christian Münz
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 4.  Vaccination against the Epstein-Barr virus.

Authors:  Julia Rühl; Carol S Leung; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2020-05-04       Impact factor: 9.261

Review 5.  Natural Killer Cell Responses during Human γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2021-06-15

6.  Germline Compound Heterozygous Variants Identified in the STXBP2 Gene Leading to a Familial Hemophagocytic Lymphohistiocytosis Type 5: A Case Report.

Authors:  Vera Maria Dantas; Cassandra Teixeira Valle; Roberta Piccin de Oliveira; Mylena Taíse Azevedo L Bezerra; Cleia Teixeira do Amaral; Raissa Anielle S Brandão; Jussara M Cerqueira Maia; Tirzah Braz Petta
Journal:  Front Pediatr       Date:  2021-06-24       Impact factor: 3.418

Review 7.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

Review 8.  Immunodeficiencies that predispose to pathologies by human oncogenic γ-herpesviruses.

Authors:  Blossom Damania; Christian Münz
Journal:  FEMS Microbiol Rev       Date:  2019-03-01       Impact factor: 16.408

Review 9.  Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection.

Authors:  Christian Münz
Journal:  Biomolecules       Date:  2021-12-28

10.  T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.

Authors:  Oded Shamriz; Deepak Kumar; Jenny Shim; Michael Briones; Maa-Ohui Quarmyne; Satheesh Chonat; Laura Lucas; Holly Edington; Michael H White; Advay Mahajan; Sunita Park; Shanmuganathan Chandrakasan
Journal:  J Clin Immunol       Date:  2021-06-26       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.